A vial of the experimental Novavax coronavirus vaccine is ready for use in a London study in 2020. Novavax's vaccine candidate contains a noninfectious bit of the virus — the spike protein — with a substance called an adjuvant added that helps the body generate a strong immune response. (AP)
